Theranexus


Theranexus, a unique clinical stage pharmaceutical company, has developed a versatile proprietary technology leading to first in class products to address severe unmet medical needs in brain disorders.

 


Who we are

Theranexus, a unique clinical stage pharmaceutical company, has developed a versatile proprietary technology leading to first in class products to address severe unmet medical needs in brain disorders.

More about who we are

Corporate

Theranexus is a French biotechnology company, created in 2013. We are an operational team supported by a network of highly experienced industrial and medical leaders in our target indications. We have developed a proprietary technology platform for generating IP protected New Therapeutic Entities that address unmet needs in CNS.

More about corporate

Technology & Products

The technology is based on the pharmaceutical modulation (not DDS) of existing and proven CNS drugs to generate a new efficacy/safety profile, enabling new IP, new indications, and premium pricing. This technology is versatile and adaptable to numerous classes of CNS drugs and indications.

More about products

News

Recent news :

May 17th, 2016 - Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS)

March 30th, 2016 - Preclinical results published in the specialist medical journal Sleep, Phase II entry of THN102

See out news